TOPLINE: Immune-related adverse events (irAEs) were associated with significantly improved progression-free survival (PFS) and overall survival (OS) in patients with extensive-stage small cell lung cancer (SCLC) who received chemoimmunotherapy compared with that in those who did not experience such events. METHODOLOGY: Researchers conducted a retrospective analysis of 399 consecutive patients (median age...
.png)
